$ENVB News

Enveric Biosciences Announces Participation in B. Riley Securities Mind, Muscle & Vision Summit

Enveric Biosciences Announces Participation in 2026 BIO International Convention

Enveric Biosciences to Participate in the UBS 3rd Virtual CNS Day

Enveric Biosciences Initiates Investigational New Drug (IND)-enabling Genotoxicity Studies of Lead Neuroplastogen Candidate EB-003

Enveric Biosciences Initiates Investigational New Drug-enabling Genotoxicity Studies Of EB-003

Enveric Biosciences Q1 EPS $(1.08) Up From $(14.64) YoY

Enveric Highlights Preclinical PTSD Data Amid Rising Focus On Mental Health Therapies

Enveric Biosciences Highlights Results for EB-003 In PTSD Preclinical Model; Says Previously Reported Results Support Continued Development Of EB-003 For PTSD, Other Neuropsychiatric Condition

Enveric Biosciences shares are trading higher after the FDA announced accelerated efforts to advance treatments for serious mental illnesses, following an executive order signed by President Trump.

Enveric Biosciences shares are trading higher after the FDA announced accelerated efforts to advance treatments for serious mental illnesses, following an executive order signed by President Trump.

Enveric Bioscience Shares Resume Trade

Enveric Biosciences Shares Halted On Circuit Breaker To The Upside, Stock Now Up 34.58%

Enveric Biosciences Files Prospectus Related To Resale Of Up To 6.82M Shares Of Common Stock

Enveric Biosciences Canada Granted U.S. Patent Over Carboxylated Psilocybin Derivatives And Methods Of Using

Enveric Biosciences Stock Soars After Trump's Psychedelics Executive Order

Enveric Biosciences shares are trading higher after President Trump signed an executive order on accelerating medical treatments for serious mental illness.

Enveric Biosciences shares are trading lower after the company announced a $13.9 million private placement of 2,222,223 shares at $2.25 per share and accompanying warrant.

Reported Earlier, Enveric Biosciences Prices At-The-Market Private Placement Of 2.2M Shares At $2.25, Raising Up To $13.9M With Warrants

Enveric Biosciences Receives U.S. Patent For Its EVM301 Series Of Molecules

Enveric Biosciences Q4 EPS $(0.50) Up From $(57.96) YoY